A study from Fred Hutch Cancer Center finds that some cancer patients' antibodies can boost their response to immunotherapy treatment.

A new study has revealed that autoantibodies—immune proteins traditionally associated with autoimmune disease—may profoundly influence how cancer patients respond to immunotherapy.

Total neoadjuvant therapy demonstrates consistent real-world efficacy across regimens in patients with locally advanced rectal cancer, a study finds.

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called ...

Researchers say the vaccine, developed by Anixa Biosciences and funded by the Department of Defense, could eliminate breast cancer - which one out of eight women will get in her life - by 2030.

A recent study in Nature Communications, by Dr. Pauliina Munne and others, provides insight into why some patients with breast cancer do not respond to therapy. Munne is a scientist in the ...

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.

Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two ...

Even though rectal bleeding is alarming, doctors say patients are ashamed to mention it, delaying colon cancer diagnosis and treatment.

3593Background: Variation in response to radiotherapy for the treatment of rectal cancer is likely due to heterogeneity in the tumour microenvironment. However, to date, no reliable predictive ...

The radiomic features were extracted using PyRadiomics, then a radiomic feature-based model for predicting response to atezolizumab plus bevacizumab therapy was constructed using the Extreme Gradient ...